SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors show strong conviction in its proprietary Alpha DaRT oncology platform, bolstered by recent Japanese marketing approval and upcoming trial milestones. The community is actively discussing the stock's robust cash position, the absence of dilution risk, and the belief that the company is significantly undervalued as it transitions into a commercial-stage player.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending as investors react to a 31.5% stake acquisition of Distributed Technologies Research, a move that has fueled intense community debate over potential dilution versus strategic expansion into AI-driven finance. Traders are also closely watching the ticker's high beta to Bitcoin, with many speculating on upcoming announcements at the company's investor day as they weigh the stock's long-term potential against past patterns of volatility.

Praetorian Acquisition Corp. - Ordinary Shares - Class A

Investors are closely monitoring Praetorian Acquisition Corp. following its recent public debut as the market evaluates the potential for future merger and acquisition activity from the newly formed blank check company.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh its aggressive pivot toward private credit and AI-driven infrastructure against lingering concerns regarding industry-wide redemption pressures and valuation risks in the real estate sector. The community is sharply divided, with some betting on a long-term turnaround fueled by record dry powder and strategic deployment, while others are closely monitoring potential liquidity constraints that could signal broader credit cycle risks.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending as investors closely monitor for a potential tenant announcement following the recent appointment of a new CFO with an extensive background in data center financing. Community sentiment remains polarized, with many long-term shareholders bullish on the company's behind-the-meter energy strategy while others express frustration over the timing of promised project developments.

Rydex Investments - Invesco CurrencyShares Canadian Dollar Trust

Invesco CurrencyShares Canadian Dollar Trust

The Canadian dollar is experiencing heightened volatility as investors weigh persistent trade-policy uncertainties and fluctuating crude oil prices against the Bank of Canada's cautious interest rate approach. The community is actively debating the potential for further easing, keeping a close watch on how shifting trade relations and economic data impact the currency's near-term trajectory.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is experiencing significant market interest following a strong quarterly earnings report that featured a double beat on top and bottom-line expectations and raised forward-looking guidance. The community is actively discussing the stock's impressive post-earnings price surge, debating the sustainability of its robotic surgery market dominance against potential margin pressures from tariffs and broader sector volatility.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense market attention and high trading volume as investors position themselves ahead of the major OFC and GTC conferences, which the community views as critical catalysts for showcasing their optical interposer and external light source technologies. Sentiment is driven by speculation regarding potential new commercial partnerships or orders, with traders actively debating the stock's potential for a breakout amid heavy institutional accumulation and volatility around options expiration.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing intense volatility as traders weigh the impact of an ongoing conflict in the Middle East and the potential closure of the Strait of Hormuz against reports of shifting diplomatic efforts. Market sentiment remains divided between bulls betting on supply-driven price spikes and bears anticipating that increased production and coalition-building efforts will lead to a rapid price correction.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors monitor potential collaborations with Nvidia and Tesla, alongside speculative chatter regarding the company's long-term fab strategy and government support. The community remains divided, with active debates between bulls focused on deep-value, long-term AI turnaround plays and skeptical traders wary of short-term volatility and sector-wide supply chain risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Catalent, Inc. ($CTLT) CEO Alessandro Maselli said in an open <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.catalent.com/catalent-news/catalent-issues-open-letter-to-customers-regarding-pending-acquisition-by-novo-holdings/">letter</a> that he will continue to lead Catalent as President and CEO following its acquisition by Novo Holdings.“A key factor in my decision to continue in my role is Novo Holdings’ commitment to provide support and capital to ensure unparalleled service to our customers and create new jobs as we drive Catalent’s growth,” he said.Catalent is a manufacturing partner of Novo for Wegovy, a popular weight-loss drug. In February, the companies had <a target="_blank" rel="noopener noreferrer nofollow" href="https://novoholdings.dk/news/novo-holdings-to-acquire-catalent">announced</a> that Novo Holdings will acquire Catalent in an all-cash transaction that values the latter at $16.5 billion on an enterprise value basis.Novo Holdings also said it intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk ($NVO), in which Novo Holdings has a controlling interest, shortly after the closing of the merger. These three sites are located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium.However, U.S. consumer groups have been voicing concerns on how the deal could potentially affect competition in the weight-loss drugs space and cutting-edge gene therapies. They have reportedly asked the U.S. Federal Trade Commission to block the transaction.Maselli asserted in his letter that the firm’s commitments will not change, its focus will remain on its products and customers’ proprietary information will be protected.Catalent’s acquisition by Novo Holdings is expected to close towards the end of calendar year 2024.NYSE-listed shares of Novo Nordisk and Catalent were trading marginally in the red following the announcement. Retail sentiment inched up higher into the ‘neutral’ territory (47/100) from the ‘bearish’ zone a day ago.<figure class="image"><a href="https://stocktwits.com/symbol/NVO"><img style="aspect-ratio:1872/530;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_21_at_11_10_35_AM_fcc7c29587.png" alt="Novo Nordisk sentiment meter as of 10:52 a.m. ET on Oct. 21, 2024 | Source: Stocktwits" width="1872" height="530"></a><figcaption>Novo Nordisk sentiment meter as of 10:52 a.m. ET on Oct. 21, 2024 | Source: Stocktwits</figcaption></figure>Catalent shares have gained over 33% since the beginning of the year while Novo Nordisk shares are up over 14% on a year-to-date basis.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dallas-fed-president-lorie-logan-says-economys-strong-but-uncertainties-remain/cJ2a5gaReR">Dallas Fed’s Lorie Logan Says Although Economy’s Strong, Meaningful Uncertainties Remain In Outlook</a>For updates and corrections email newsroom@stocktwits.com

Catalent’s acquisition by Novo Holdings is expected to close towards the end of calendar year 2024 | Representative Image Source: Pexels

Catalent CEO Assures Continuity After Novo Holdings Buyout: Retail Investors Wait And Watch

Maselli asserted in his letter that the firm’s commitments will not change, its focus will remain on its products and customers’ proprietary information will be protected.

Equity

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Bridgewater, NJ.

CTLT
Catalent Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CTLT News

CTLTCatalent Inc.